Enlivex Pharmaceuticals Ltd., is a clinical stage immunotherapy company,  developing an autologous and allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) for which there are no FDA-approved treatments (unmet medical need), as well as solid tumors immune-checkpoint rebalancing.  The company’s drug therapy presents a novel immunotherapy mechanism of action that targets clinical indications that are considered to be untreatable such as Graft-versus-Host disease (GvHD) resulting from bone-marrow transplantations, Sepsis and acute multiple organ failure, and effective treatment of solid tumors via immune checkpoint reprogramming increasing efficacy of CAR-T, TCR and other anti-cancer therapies.


Designed & Powered by SCOOP